ClinicalTrials.gg

Program

BCD-248

A development code. Also written as “BCD-248 + daratumumab”.

Its studies are mostly in Multiple Myeloma, led by Biocad.

Furthest: phase 3, since Jul 23, 20262 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocad22 open or runningphase 3since Jul 23, 2026Oct 30, 2024Jul 2028phase 3 · NCT07742215

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2024First study: phase 2 study in Multiple MyelomaFirst studyNCT06668792 · 100 planned · Russian Federation
  2. Jul 23, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07742215 · 390 planned · Belarus, Russia

Ahead

  1. Jul 2028Primary completion: phase 3 study in Multiple MyelomaNCT07742215

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07742215Multiple Myeloma · Belarus, Russia3RecruitingJul 2028390
NCT06668792Multiple Myeloma · Russian Federation2RecruitingFeb 2026100

How it is read

Names in the registry

  • “BCD-248 + daratumumab”, 1 entry
  • “BCD-248”, 1 entry

Codes read as this program: BCD248.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.